EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Real-World Data on the Effectiveness of Immunotherapy on Advanced NSCLC: A Retrospective Cohort Study

Antonios Katsarolis iD, Iliana Tapazidou-Spanoudi, Dimitris Kugiumtzis iD, Nikoleta Pastelli, Dionisios Spyratos, Katerina Manika, Anastasios Vagionas, Sofia Lampaki, Elena Fountzilas

Cancers · 14.04.2026 · 18 (8) · 1239

DOI: 10.3390/cancers18081239 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancers, online erschienen am 14.04.2026. Verfasst von Antonios Katsarolis und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HeSMO, Hellenic Society of Medical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The aim of the study was to evaluate the real-world effectiveness of immunotherapy compared to chemotherapy in advanced non-small-cell lung cancer (NSCLC) and assess molecular profiling patterns in a large Greek cohort.

Methods

This was a retrospective study of patients with advanced NSCLC from three oncology centers. Clinical, pathological, and/or molecular data were collected from the patient medical records. The primary endpoint was overall survival (OS).

Results

Overall, 684 patients with advanced NSCLC were included; median age 67 years (range, 33 to 89). More than half of the patients (406, 59.4%) had been diagnosed with de novo metastatic disease. Overall, 289 of 684 (42.3%) patients underwent tumor molecular profiling. Immunotherapy use, with or without chemotherapy, in the first-line setting increased significantly over time (p < 0.001). Among 610 patients eligible for outcome analysis, immunotherapy at any line of treatment was associated with increased OS compared to chemotherapy alone (17.5 vs. 8.6 months; HR: 0.51, 95% CI: 0.42, 0.61; p < 0.001). The results remained consistent with the primary analysis as well as the landmark analysis using a 3-month cutoff to account for the immortal-time bias. Furthermore, time to next treatment (TTNT) was significantly longer with immunotherapy use in both first- and second-line treatment (TTNT1: 10.0 vs. 6.8 months, HR: 0.45, 95% CI: 0.34, 0.58; p < 0.001; TTNT2: 6.7 vs. 5.9 months, HR: 0.59, 95% CI: 0.40, 0.87; p = 0.009). Immunotherapy use remained an independent predictor of improved survival (HR: 0.50, 95% CI: 0.40, 0.63; p < 0.001).

Conclusions

Immunotherapy, with or without chemotherapy, significantly improved clinical outcomes compared to chemotherapy alone in a real-world cohort of patients with advanced NSCLC. While molecular testing rates increased significantly over the study, only a minority of patients underwent PD-L1 testing, while broad molecular profiling was also incomplete, limiting the interpretation of treatment effects. Improvements to guarantee the universal molecular testing of patients with NSCLC are warranted.

Schlagwörter

Stichwörter der Autor:innen

effectivenessimmunotherapynon-small-cell lung cancerreal-world datasurvival

Autor:innen und Institutionen

  • School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
  • School of Electrical and Computer Engineering, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Department of Pathology, "George Papanikolaou" General Hospital, 57010 Thessaloniki, Greece.
  • Oncology Unit, Pulmonology Clinic, "George Papanikolaou" General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Oncology Department, General Hospital of Kavala, 65500 Kavala, Greece.

ORCID-Profile: Antonios Katsarolis, Dimitris Kugiumtzis

Förderung

  • HeSMO
  • Hellenic Society of Medical Oncology

Zitieren

APA

Katsarolis, A., Tapazidou-Spanoudi, I., Kugiumtzis, D., Pastelli, N., Spyratos, D., Manika, K., Vagionas, A., Lampaki, S., & Fountzilas, E. (2026). Real-World Data on the Effectiveness of Immunotherapy on Advanced NSCLC: A Retrospective Cohort Study. Cancers, 18(8), 1239. https://doi.org/10.3390/cancers18081239

Vancouver

Katsarolis A, Tapazidou-Spanoudi I, Kugiumtzis D, Pastelli N, Spyratos D, Manika K, et al. Real-World Data on the Effectiveness of Immunotherapy on Advanced NSCLC: A Retrospective Cohort Study. Cancers. 2026;18(8):1239. doi:10.3390/cancers18081239

BibTeX
@article{Katsarolis2026,
  author = {Katsarolis, Antonios and Tapazidou-Spanoudi, Iliana and Kugiumtzis, Dimitris and Pastelli, Nikoleta and Spyratos, Dionisios and Manika, Katerina and Vagionas, Anastasios and Lampaki, Sofia and Fountzilas, Elena},
  title = {Real-World Data on the Effectiveness of Immunotherapy on Advanced NSCLC: A Retrospective Cohort Study},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1239},
  doi = {10.3390/cancers18081239}
}
Kostenlos starten →